ALLGRAM-CV-200
Description
- Contains Cefixime 200 mg (cephalosporin antibiotic) and Clavulanic Acid 125 mg (β-lactamase inhibitor)
- Effective against resistant bacterial strains by preventing antibiotic degradation
- Treats a wide range of infections: respiratory, urinary, ENT, and soft tissue
- Especially useful for infections caused by β-lactamase–producing organisms
- Excellent oral bioavailability and well-tolerated profile
- Prescribed for adults and adolescents under medical supervision
- Convenient dosing with enhanced therapeutic efficacy
Composition
Cefixime 200 mg + Clavulanic Acid 125 mg
Benefits
ALLGRAM-CV-200 offers superior efficacy in managing moderate to severe bacterial infections by combining the bactericidal power of Cefixime with the resistance-blocking action of Clavulanic Acid. It is particularly effective in treating bronchitis, pneumonia, tonsillitis, sinusitis, and urinary tract infections caused by β-lactamase-producing organisms. The formulation helps reduce the risk of treatment failure and recurrence of infection. With once or twice-daily dosing and excellent oral absorption, ALLGRAM-CV-200 ensures patient compliance and faster recovery with minimal side effects.
Introduction
ALLGRAM-CV-200 is a broad-spectrum antibiotic formulation containing Cefixime 200 mg, a third-generation cephalosporin, and Clavulanic Acid 125 mg, a β-lactamase inhibitor. This synergistic combination enhances the effectiveness of Cefixime by overcoming bacterial resistance mechanisms, making it a powerful solution for treating a wide range of bacterial infections. ALLGRAM-CV-200 is commonly prescribed for respiratory tract infections, urinary tract infections, ENT infections, and other conditions where resistant bacteria are suspected. Its dual-action approach ensures enhanced bacterial coverage and reliable therapeutic outcomes.
